Skip to content

A clinical study of XieHuoXiaoYing Formula in the treatment of Graves Disease in the early stage with heart and liver fire flaming syndrome

A clinical study of XieHuoXiaoYing Formula in the treatment of Graves Disease in the early stage with heart and liver fire flaming syndrome

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800015343
Enrollment
Unknown
Registered
2018-03-24
Start date
2018-04-01
Completion date
Unknown
Last updated
2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves disease

Interventions

xiehuoxiaoying group:XieHuoXiaoYing formula combined with Methimazole
Methimazole group: Methimazole

Sponsors

Jiangsu Province Hospital of Integrated Traditional Chinese and Western Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. meet with the diagnostic criteria of Graves disease; 2. meet with the diagnostic criteria of traditional Chinese medicine of heart and liver fire flaming syndrome; 3. aged between 18-70 years old, and the patients have independent behavioral ability; 4. Patient understands the whole process of clinical research and has signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Combines basic diseases such as cardiovascular, cerebrovascular, liver, kidney and hematopoietic systems, and psychotic patients; 3. There are serious hyperthyroid complications, complications and other patients; 4. Kind of allergies and various drug allergies; 5. Patients who fail to comply with regulations or frequently change the working environment may result in failure to follow up. Patients who do not reach the established observation period and give up treatment cannot determine the effect of drug treatment or the incompleteness of relevant materials; 6. At the same time, patients are still undergoing other clinical trials.

Design outcomes

Primary

MeasureTime frame
rate of stop medication;

Secondary

MeasureTime frame
thyroid function;

Countries

China

Contacts

Public ContactChao Liu
profliuchao@163.com+86 15851817839

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026